We have previously shown that the adoptive transfer of splenocytes, isolated from mice immunized by infection with the paramyxovirus simian virus 5 (SV5), enhance the speed of clearance of SV5 from the lungs of immunodeficient mice; clearance is mediated primarily through CD8+ effector cells and not by serum neutralizing antibody (D. F. Young, R. E. Randall, J. A. Hoyle, and B. E. Souberbielle, J. Virol. 64:5403-5411, 1990). In this article we demonstrate that immunization of mice with solid matrix-antibody-antigen (SMAA) complexes also induces CD8+ effector cells that are responsible for clearing persistent SV5 infections in immunodeficient mice. The demonstration that immunization with SMAA complexes (an exogenous antigen) can induce class I-restricted cytotoxic T lymphocytes (CTLs) suggests that these cells may be responsible for virus clearance in vivo. This premise is supported indirectly by the observation that immunization with SMAA complexes was less efficient in inducing class I-restricted CTLs (as measured in vitro) than was infectious virus and that splenocytes isolated from mice immunized with SMAA complexes were also less efficient in clearing virus from lungs of immunodeficient mice than were splenocytes isolated from mice immunized by infection with virus. This was not because the SMAA complexes were generally less immunogenic than infectious virus, since mice immunized with SMAA complexes (which contained the HN protein of SV5) produced higher levels of neutralizing antibody than mice immunized with infectious virus. In the majority of experiments, fixed and killed suspensions of Staphylococcus aureus Cowan strain A were used as the solid matrix in the construction of SMAA complexes. However, in this article we present evidence that alum-antibody-antigen complexes are as immunogenic as S. aureus A-antibody-antigen complexes. These results suggest that the immunological reactivity of the solid matrix itself does not influence the intensity of the immune response to the antigens of interest in the SMAA complexes. The significance of these results for vaccine design are discussed.
Antibodies and T lymphocytes play critical roles in prevention of and recovery from viral infections. Effector antibody responses are primarily concerned with the inactivation, or neutralization, of free virus. Cytotoxic T cells (CTLs) recognize and kill infected cells, thus reducing or preventing the production of progeny virus. In addition, T cells may release antiviral lymphokines, such as gamma interferon, that inhibit virus replication. While neutralizing antibodies interact with antigens located on the surface of the virus particle, T cells may potentially recognize target antigens on any virus protein (for a review of how antigens are recognized by B and T lymphocytes, see reference 25) . In order to induce long-lived protective immunity by vaccination against certain virus diseases, it may therefore be necessary to induce a broad immune response with the expansion of both B-and T-cell clones that recognize many different target antigens on different virus proteins. Consequently, in such situations it may be necessary to incorporate multiple antigens into a vaccine. We have suggested that one way of constructing such vaccines may be through the design and manufacture of solid matrix-antibody-antigen (SMAA) complexes (24, 26, 27) .
T lymphocytes recognize virus antigens, as peptides, in association with either class I or class II major histocompatability (MHC) antigens. In general, CTLs recognize virus antigens in association with class I MHC molecules, while T helper/inducer cells recognize antigens in association with class II MHC molecules (for review, see reference 3) . Thus, * Corresponding author.
in the majority of virus infections, class I-restricted CTL responses are the predominant response (6-8, 12, 21, 39) , although for some viruses it appears that class TI-restricted CTLs may also be important (16, 17, 20, 30, 36) . Class I-and class IT-restricted T cells can be distinguished by monoclonal antibodies to cell surface antigens, those recognizing class I MHC antigens having a CD8+ CD4-phenotype and those recognizing class II MHC antigens having a CD4+ CD8-phenotype (31) .
It is well documented that exogenous antigen is normally processed through an endosomal pathway for class II MHC presentation (1) . However, there is a body of evidence which suggests that exogenous antigens (e.g., noninfectious virus antigens) are not normally processed in a way which leads to the successful induction of class I-restricted CTLs, whereas endogenous antigens (e.g., virus proteins made in infected cells) are (9, 13, 23) . This may be because for virus antigens to become associated with class I MHC molecules, they have to be processed within the cytosol of antigen-presenting cells (22, 34, 37) . Nevertheless, it has been reported that class I-restricted CTLs can be generated in vivo after immunization with noninfectious virus antigens, e.g., recombinant hepatitis B virus vaccine (18) , the NP protein of influenza virus (35) , and a hybrid influenza virus HA protein (19) . Class I-restricted CTL induction has also been de- scribed with ovalbumin as the immunizing antigen (32 (26) .
We have previously demonstrated that immunization of mice with SMAA complexes containing either internal or surface structural proteins of the paramyxovirus SV5 enhances the speed of clearance of the virus from the lungs of infected immunocompetent mice (29) [14] ) was grown and titrated under appropriate conditions in Vero or BHK cells in medium containing 2% newborn calf serum.
X-irradiation of mice. BALB/c mice (6 to 8 weeks old) were exposed to 5 Gy of whole-body X-irradiation prior to infection with SV5. Immediately following X-irradiation of mice, their splenocytes failed to respond to the B-cell mitogen lipopolysaccharide and the T-cell mitogen concanavalin A. Ten days after irradiation, the spleens had atrophied to such an extent that only 2 x 106 to 4 x 106 splenocytes could be isolated per spleen, versus 1 x 108 to 2 x 108 from a normal spleen. The few splenocytes isolated from X-irradiated mice at this time showed some activation by concanavalin A but none by lipopolysaccharide. X-irradiated mice do however begin to recover their ability to mount an immune response 2 to 3 weeks after irradiation (2) , and by 10 Fig. 1 and 5). Mice were immunized twice intraperitoneally (i.p.) with 2 to 5 ,ug of antigen presented as alum-Ab-Ag complexes or St. A-Ab-Ag complexes. When mice were immunized with more than one virus protein, e.g., HN, NP, P, and M, the proteins were purified as separate SMAA complexes, which were then mixed together prior to immunization. A gap of 3 to 4 weeks was left between the first and second immunizations, and 10 to 14 days after the second immunization the mice were bled, and the sera were collected and stored at -20°C until required.
Adoptive transfer of different lymphocyte populations to immunodeficient mice. BALB/c (H-2d) mice were immunized with either SMAA complexes (i.p.) or infectious virus (by the nasal route) as described above. Spleen cells were isolated from immune mice 4 to 6 weeks after the second immunization by standard methods. From 2 x 107 to 4 x 107 unselected or selected (below) lymphocytes were adoptively transferred by i.p. inoculation in PBS. CD8+ or CD4+ cells were sensitized for complement lysis and opsonization with MAbs (clones YTS 169.4 and YTS 191.1, respectively) specific for these cell surface antigens (10, 11) prior to their adoptive transfer. Briefly, 5 x 107 cells were incubated for 15 min at 37°C in 1 ml of antibody (as ascitic fluid; Sera-Lab, Crawley Down, England) that had been diluted 1:50 in PBS which also contained guinea pig complement at a final dilution of 1:40 (Sera-Lab). The cell-antibody mixtures were adoptively transferred to mice (10, 11 min at 4°C and washed once with 10 ml of PBS, and the percentage of fluorescent cells in 10,000 events was determined by using the LYSYS program on a Becton Dickinson FACScan.
Cytotoxicity assays. Spleens were removed from immune mice 4 to 6 weeks after their second immunization. Splenocytes were restimulated in vitro twice (at the time the cultures were set up and after 5 days in culture) with SV5-infected spleen cells in the manner described for the generation of CTLs specific for respiratory syncytial virus (5) . The level of CTL activity was measured in these cultures in 4- Preparation of radiolabeled antigen extracts, immunoprecipitation, and SDS-PAGE. The methods for these techniques have been described elsewhere (28) . In the preparation of soluble antigen extracts, the immunoprecipitation buffer used consisted of 20 mM Tris hydrochloride (pH 7.2), 5 mM EDTA, 0.5% Nonidet P-40, 0.1% SDS, 0.65 M NaCl, and protease inhibitors (1 mM phenylmethylsulfonyl fluoride and 10 mM NaS205). The polypeptides present in SMAA complexes were analyzed by electrophoresis through thin (0.4 mm) minislab gels (4 by 8 cm) with a Uniscience (London, United Kingdom) mini vertical electrophoresis system. Polypeptides separated for Western immunoblot analysis were separated through larger polyacrylamide slab gels (14 by 18 cm) of greater thickness (2 mm).
Western blot analysis of lung extracts from SV5-infected mice. Lungs were homogenized in SDS-PAGE disruption buffer (28) , sonicated with an MSE ultrasonic probe, and heated for 5 min at 100°C. Particulate material was pelleted by centrifugation (6,000 x g for 3 min), and the dissociated polypeptides were separated by electrophoresis through a 15% SDS-polyacrylamide slab gel. The separated polypeptides were transferred to nitrocellulose with a semidry gel electroblotter (LKB). The nitrocellulose was then reacted with a pool of MAbs to the P protein (28) , and bound antibody was detected by 125I-labeled protein A and autoradiography as described previously (29) .
Neutralization test. Twofold dilutions of sera (100 I,l) in tissue culture medium containing 2% newborn calf serum were incubated at 37°C for 2 h with 100 ,ul of SV5 (5 x 105 PFU/ml). The antibody-virus mixtures were then used to infect Vero cells growing as monolayers in 96-well microtiter plates. The cells were incubated at 37°C for a further 30 to 40 h. The cells were then fixed with 5% formaldehyde-2% sucrose in PBS for 10 min, permeabilized with 0.5% Nonidet P-40-10% sucrose in PBS for 5 Mice were immunized either by prior infection with SV5 or by injection with mixtures of St. A-Ab-Ag complexes (exogenous antigen) containing the HN, NP, P, and M proteins of SV5 (Fig. 1) . Splenocytes isolated from mice immunized either by infection with SV5 or with SMAA complexes were capable of killing virally infected cells in an MHC-restricted manner as assayed in standard chromium release tests. Thus, immune splenocytes isolated from BALB/c mice (H-2d) following restimulation in culture killed SV5-infected P815 (H-2d) cells but not uninfected P815 cells. They also failed to kill infected or uninfected target cells which had a different MHC haplotype than BALB/c cells (Fig. 2) . Since P815 cells express class I MHC antigens but not class II MHC antigens, these results confirm that immunization with SMAA complexes can induce class I-restricted CTLs. Interestingly, however, the level of CTL activity in animals immunized by prior infection with SV5 was greater than that in mice immunized with SMAA complexes. Indeed, while high levels of CTL activity could be detected in 4-day-stimulated cultures of splenocytes isolated from mice immunized by infection with virus, only low levels of CTL activity could be detected in splenocytes isolated from animals immunized with SMAA complexes. However, in agreement with our previous results (29) , high levels of CTL activity were detected in 10-day-restimulated cultures of splenocytes isolated from mice immunized with SMAA complexes (Fig. 2) .
Clearance These cells were transferred to immunodeficient mice immediately after they had been infected with virus. Animals were sacrificed 10 In order to identify the lymphocytes responsible for virus clearance, CD4+ and CD8+ cells were specifically depleted from immune splenocytes by complement lysis. In these experiments, although untreated splenocytes isolated from mice immunized with St. A-Ab-Ag complexes (containing the HN, NP, P, and M proteins of SV5; Fig. 1 ) enhanced the speed of clearance of virus from the lungs of immunodeficient mice, depletion of CD8+ cells abolished the protection observed (Fig. 3) . It is also of note that mice which received immune splenocytes depleted of CD8+ cells made higher levels of serum neutralizing antibody than mice which received untreated immune splenocytes that enhanced the speed of clearance of virus (data not shown). naive CD8+ effector cells in vivo, which were responsible for the clearance observed.
To examine this possibility, a series of lymphocyte mixing experiments were performed. CD8+ cells were depleted by complement lysis from a population of immune splenocytes (isolated from mice immunized with SMAA complexes) in which class I-restricted CTL activity could be demonstrated in vitro (Fig. 2) . Although untreated immune splenocytes were capable of clearing the virus infection, following depletion of CD8+ cells the remaining cells were unable to clear the virus infection. Furthermore, when equal numbers of immune splenocytes depleted of CD8+ cells were mixed with nonimmune splenocytes containing CD8+ cells prior to their adoptive transfer, this mixed population of cells also failed to clear the virus infection (Fig. 4) alum-Ab-Ag complexes (containing the HN and NP proteins; Fig. 5 ), or infectious virus. The level of neutralizing antibody in the sera of these mice was measured (Table 1) .
Mice immunized with either St. A-Ab-HN/NP complexes or alum-Ab-HN/NP complexes had higher levels of neutralizing activity than animals immunized by prior infection with SV5. Indeed, the highest titers of serum neutralizing antibody were detected in mice immunized with alum-Ab-HN/NP complexes (Table 1) . These animals were then killed, and different numbers of splenocytes were adoptively transferred to immunodeficient mice that had been infected with SV5. The amount of virus in these mice was estimated 10 days postinfection by Western blot analysis with a pool of MAbs specific for the P protein (Fig. 6) . These results clearly demonstrate that splenocytes isolated from mice immunized with alum-Ab-HN/NP complexes were capable of clearing the infection. Furthermore, depletion of CD8+ cells from mice immunized with alum-Ab-Ag complexes abolished the ability of splenocytes isolated from these animals to clear the virus infection (data not shown). However, immunization with infectious virus was more efficient in inducing effector cells responsible for virus clearance than immunization with either St. A-Ab-Ag complexes or alum-Ab-Ag complexes. Thus, transfer of 1.6 x 106 splenocytes from mice immunized with infectious virus cleared the infection in 50% of the animals tested (in the absence of serum neutralizing antibody; Table 2 ), but the same number of splenocytes isolated from mice immunized with SMAA complexes failed to clear the infection in all animals (Fig. 6 ). This was despite the fact that mice which had received splenocytes from animals a Different numbers of splenocytes isolated from these mice were adoptively transferred to immunodeficient mice, and their ability to clear virus by 10 days postinfection was measured (Fig. 6) , as was their titer of serum neutralizing antibody (Table 2 ). immunized with alum-Ab-HN/NP complexes had the highest titers of serum neutralizing antibodies (Table 2 ).
DISCUSSION
We have previously shown that SV5 establishes a persistent infection in mouse lungs and that neutralizing antibodies (38) , it is clear that in other virus infections serum neutralizing antibodies are protective. Indeed, to produce successful vaccines against a number of virus diseases, it may be important to induce both specific antibody and T-cell responses. While there are many potential advantages in producing noninfectious subunit vaccines, there aIso a number of problems to be overcome (25) . One problem was thought to be that exogenous antigen could not induce class I-restricted T cells. We and others have now clearly demonstrated that this is not the case. However, the SMAA complexes used in this study are significantly less efficient in inducing class I-restricted T cells than infectious virus. By further understanding how exogenous antigen is processed for association with class I MHC antigens and by identifying the cell types involved in processing exogenous antigen for class I MHC presentation, it may be possible to devise more effective ways for inducing CD8+ cells with exogenous antigen, e.g., by targeting the binding of antigens to specific antigen-presenting cells or by directing antigens to particular intracellular processing pathways by influencing how they are taken up by antigen-presenting cells.
We have suggested that the manufacture of SMAA complexes may be one method for producing multivalent subunit vaccines (24) . However, in the majority of our experiments on SMAA complexes, we used fixed and killed suspensions of S. aureus Cowan strain A as the solid matrix, which at present would not find favor for widespread use in humans.
Our initial results presented here demonstrate that alumAb-Ag complexes are as immunogenic as St. A-Ab-Ag complexes, both in their ability to induce antibody responses and in their ability to induce effector cells responsible for clearing SV5 infections from immunodeficient mice. These results therefore suggest that the immunogenicity of the solid matrix itself does not influence the immune response to the antigens of interest in the SMAA complexes. Rather, the presentation of antigens in a particulate form and possibly in repeating motifs may be of greater importance. In addition, it is possible that the presence of antibody bound to antigen may trigger immunological reactions (e.g., activation of the complement system) that will enhance the immune response to the SMAA complexes. Concerning the activation of T cells by SMAA complexes, the fact that the protein of interest is not bound directly to the solid matrix (or precipitated in it) may also be particularly advantageous. It can be speculated that proteins precipitated in alum or directly absorbed onto alum may not be processed correctly by antigen-presenting cells; this would explain why previous results have shown that antigens bound directly to alum have been poor inducers of T cells. While further work is required to answer these questions, it is clear that it should be possible to design inert solid matrices as carriers for antibody-antigen complexes for use in human vaccines, and indeed alum itself may prove suitable for this purpose.
